Understanding the Molecular Mechanisms of Fibromuscular Dysplasia

了解纤维肌发育不良的分子机制

基本信息

批准号：
10162658
负责人：
Daniella Kadian-Dodov
金额：
$ 71.92万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-15 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10162658
关键词：
Address Adhesions Adult Affect Age Aneurysm Apoptosis Arteries Atomic Force Microscopy Beds Biological Biomechanics Blood Vessels Cardiovascular system Cells Cervical Cessation of life Clinical Complex Coronary artery Cytoskeletal Modeling Data Development Diagnosis Disease Dissection Embryo Endothelial Cells Endothelium Etiology Exhibits Fatal Outcome Female Fibroblasts Fibromuscular Dysplasia Fibrosis Genes Genetic Genetic study Genomics Goals Histopathology Human Hypertension Impairment In Vitro Ischemia Knock-out Knowledge Liquid Chromatography Medical Mesentery Molecular Mus Myocardial Infarction Names National Heart, Lung, and Blood Institute Pathogenesis Patients Pattern Phenotype Pilot Projects Prevalence Production Property Proteins Proteomics Rare Diseases Regulator Genes Reporter Reporting Resolution Role Ruptured Aneurysm Sampling Series Smooth Muscle Myocytes Stenosis Stroke Surface System Techniques Tunica Media Vascular Smooth Muscle Woman angiogenesis base cardiovascular effects in vitro Assay in vivo insight knock-down malformation migration overexpression recognins renal artery response senescence single-cell RNA sequencing tandem mass spectrometry tool transcriptome sequencing ubiquitin-protein ligase working group

项目摘要

PROJECT SUMMARY Fibromuscular dysplasia (FMD) is an understudied and sometimes fatal medical enigma that can cause arterial fibrosis, stenosis, dissection, tortuosity, aneurysm and occlusion, throughout the body. Mean age at diagnosis is 50- 55 yrs and 94% are female. Although it has a prevalence of up to 5% in females, there is no specific treatment, and very little is known about its etiology. In the press, this lack of knowledge, underappreciated prevalence and sometimes fatal outcomes have led to FMD being called “The Rare Disease That Isn’t” (WSJ, June 27, 2009). Our team, world leaders in FMD, have advanced our knowledge of its clinical features. To address the lack of understanding about its cause, in 2013 we initiated the DEFINE-FMD study - a large, functional ‘omics study of the genetic and molecular basis of FMD. Already, DEFINE-FMD has helped provide important insights into the cause of FMD, showing that it has a complex (non-Mendelian) genetic basis. Here, we propose detailed functional and mechanistic studies to understand a top causal candidate for FMD that was identified in the DEFINE-FMD study – a critical regulatory gene network (RGN) we refer to as the “FMD-RGN.” Using differing approaches, we have repeatedly validated the association of this RGN with FMD, with P values consistently less than 1 x 10-16. In addition, we have identified that one of the top key drivers of the FMD-RGN is UBR4 (ubiquitin protein ligase E3 component n- recognin 4). UBR4 is a strong causal candidate for FMD, and we have already confirmed that it exerts strong effects on modulating the expression levels of other genes in the FMD-RGN. As our overall goals we aim to determine the specific effects of the FMD-RGN on the vascular cell and arterial phenotypes, and to understand the role of UBR4 in governing the FMD-RGN and in causing FMD. • In Specific Aim 1 we will undertake detailed analyses of the impact of UBR4 and the FMD-RGN on the cellular phenotype. We will perform a series of in vitro studies using human fibroblasts with knockdown and overexpression of UBR4 to understand the role of this gene and the FMD- RGN in FMD. • In Specific Aim 2 we will characterize the in vivo cardiovascular effects of cell-specific Ubr4 deletion. We will perform a series of in vivo studies in mice with endothelial-, smooth muscle cell-, and fibroblast- specific Ubr4 deletion. We will provide a detailed characterization of the cardiovascular phenotypes of these mouse lines, including histopathology, biomechanical properties by atomic force microscopy, and proteomics using liquid chromatography tandem mass spectrometry. • In Specific Aim 3 we will perform further studies to understand the in vivo fate and function of vascular cells expressing UBR4. We will apply single cell RNA sequencing and other cutting edge techniques to freshly obtained mouse and human artery samples to provide a decisive in vivo characterization of human UBR4-expressing vascular cells, and the cell-specific phenotypic effects of Ubr4 deletion in mice. Collectively, using these integrated but independent approaches, this R01 will fully dissect the molecular mechanisms of UBR4 and the FMD-RGN, to build a holistic functional picture of the vascular pathobiology of FMD. As a disease first reported in 1938, we believe these proposed studies on FMD are imperative, and long overdue.

项目概要纤维肌性发育不良 (FMD) 是一个尚未得到充分研究、有时甚至是致命的医学谜题，它可能导致动脉粥样硬化全身纤维化、狭窄、夹层、迂曲、动脉瘤和闭塞，诊断时的平均年龄为 50 岁。 55岁，94%为女性，虽然女性患病率高达5%，但尚无特效治疗方法。媒体对其病因知之甚少，缺乏认识，其患病率也未被充分认识。有时致命的结果导致口蹄疫被称为“并非罕见的疾病”（《华尔街日报》，2009 年 6 月 27 日）。我们的团队是口蹄疫领域的世界领导者，他们提高了我们对其临床特征的了解，以解决口蹄疫缺乏的问题。为了了解其原因，我们于 2013 年启动了 DEFINE-FMD 研究——一项针对 FMD 的大型功能性组学研究。 DEFINE-FMD 已经为 FMD 的遗传和分子基础提供了重要的见解。 FMD，表明它具有复杂的（非孟德尔）遗传基础在这里，我们提出了详细的功能和原理。机制研究，以了解 DEFINE-FMD 研究中确定的 FMD 的首要候选因果关系 - 我们将关键调控基因网络 (RGN) 称为“FMD-RGN”。反复验证了该 RGN 与一致 FMD 的关联，P 值小于 1 x 10-16 此外，我们已经确定 FMD-RGN 的最关键驱动因素之一是 UBR4（泛素蛋白连接酶 E3 成分 n-）认识到 UBR4 是 FMD 的一个强有力的候选者，我们已经证实它具有很强的作用。作为我们的总体目标，我们的目标是确定 FMD-RGN 中其他基因的表达水平。 FMD-RGN 对血管细胞和动脉表型的具体影响，并了解 UBR4 在 • 在具体目标1 中，我们将对FMD-RGN 进行详细分析。 UBR4 和 FMD-RGN 对细胞表型的影响我们将使用该方法进行一系列体外研究。敲低和过度表达 UBR4 的人成纤维细胞，以了解该基因和 FMD 的作用 RGN 在 FMD 中的应用 • 在具体目标 2 中，我们将描述细胞特异性 Ubr4 的体内心血管效应。我们将在具有内皮细胞、平滑肌细胞和成纤维细胞的小鼠中进行一系列体内研究。我们将提供这些小鼠心血管表型的详细特征。线，包括组织病理学、原子力显微镜的生物力学特性以及使用液体的蛋白质组学 • 在特定目标3 中，我们将进行进一步的研究以了解。我们将应用单细胞 RNA 测序来研究表达 UBR4 的血管细胞的体内命运和功能。其他尖端技术对新鲜获得的小鼠和人类动脉样本提供了决定性的体内表达人类 UBR4 的血管细胞的表征以及 Ubr4 缺失的细胞特异性表型效应总的来说，使用这些集成但独立的方法，R01 将全面剖析分子。 UBR4 和 FMD-RGN 的机制，以构建 FMD 血管病理学的整体功能图。作为 1938 年首次报道的一种疾病，我们认为这些针对 FMD 的研究势在必行，而且早就该进行了。